National Institute of Allergy and Infectious Diseases; Notice of Closed Meetings, 1939-1940 [2012-459]
Download as PDF
<![CDATA[
1939
Federal Register / Vol. 77, No. 8 / Thursday, January 12, 2012 / Notices
Background and Brief Description
Tobacco use remains the leading
preventable cause of disease and death
in the United States, resulting in
approximately 440,000 deaths annually.
Smokers die an average of 14 years
earlier than non-smokers. Moreover,
cigarette smoking costs more than $193
billion; $97 billion in lost productivity
plus $96 billion in health care
expenditures. Although the prevalence
of current smoking among adults in the
United States has declined significantly
since 1964, in more recent years (2004
to 2010) these declines have slowed or
stalled with 1 in 5 adults reporting
current smoking. In addition, promotion
of non-cigarette tobacco products is
leading to increased diversity of tobacco
product usage, including the use of
multiple products.
With passage of the Family Smoking
Prevention and Tobacco Control Act
(FSPTCA) in 2009, the Food and Drug
Administration is legally mandated to
regulate tobacco products for the
protection of public health. Congress
passed the FSPTCA to discourage
tobacco use among minors and young
adults, to encourage cessation among
adult smokers and to reduce the public
health burden of tobacco related disease
in the U.S. Under the Tobacco Control
Act, FDA has been granted broad
authority to use the best available
science to develop and implement
effective strategies to protect the
public’s health. FDA authority includes
setting and enforcing standards for
system. While NATS has been redesigned to meet the critical data needs
of the FDA, many of the measures are
relevant to CDC’s National Tobacco
Control Program (NTCP), and CDC also
will use the NATS data to evaluate the
NTCP. Many of the NATS questions
reflect CDC’s key outcome indicators for
evaluating tobacco control programs.
CDC proposes to conduct three annual
cycles of the National Adult Tobacco
Survey (NATS) to collect data necessary
to evaluate the effectiveness of FDA’s
initial regulatory actions. The NATS
will be a stratified, random-digit dialed
telephone survey of noninstitutionalized adults 18 years of age
and older. To yield results that are
representative nationally, information
will be collected from 56,250 landline
respondents. In addition, to include the
growing population of households that
exclusively use cell phones and would
be missed in a survey relying only on
land-lines, information will be collected
from 18,750 cell phone respondents
who do not have a landline. To obtain
the target number of completed
telephone interviews, approximately
166,000 respondents will be contacted
for initial eligibility screening.
Response is voluntary. Study results
will have significant implications for
the development and periodic
adjustment of policies and programs
aimed at preventing and reducing
tobacco use in the United States. There
are no costs to respondents except their
time.
tobacco product ingredients and design,
establishing good manufacturing
practices, instituting tobacco product
labeling and health warnings;
prohibiting marketing that is misleading
to consumers and developing
enforcement authorities to act quickly
and effectively to remove violating
products. In addition, the FSPTCA gives
FDA the authority to assert jurisdiction
over cigars and other currently
unregulated tobacco products. Finally,
FDA’s regulatory authority involves
considering whether the marketing of
tobacco products might encourage
people who don’t use tobacco products
to begin using them, encourage people
who might otherwise quit to continue
using tobacco, or encourage former
users to relapse.
In order to ensure that FDA is in
compliance with the Tobacco Control
Act’s mandate to protect the public
health, annual data collection is needed
at least initially to monitor the benefits
and potential adverse consequences of
FDA’s regulatory actions, as the
regulatory framework is being
established. The FDA must regularly
monitor patterns of tobacco product
usage—novel tobacco products as well
as cigarettes—to identify changes in
susceptibility and rates of tobacco use
initiation, perceptions regarding tobacco
use, and rates of tobacco use cessation.
Rather than develop a completely new
system to monitor measures critical to
FDA, and thereby increasing burden to
the population, FDA has partnered with
CDC to leverage the existing NATS
ESTIMATED ANNUALIZED BURDEN HOURS
Number of
respondents
Number of
responses per
respondent
Average
burden per
response
(in hours)
Total burden
(in hours)
Type of respondent
Form name
Adults ages 18 or older ....................
Screener for land-line users (pp 67–
78 of the NATS).
Screener for cell phone users (pp
79–86 of the NATS).
National Adult Tobacco Survey (pp
5–66 of the NATS)—landline.
National Adult Tobacco Survey (pp
5–66 of the NATS)—cell phone.
125,000
1
2/60
4,167
41,000
1
1/60
683
56,250
1
20/60
18,750
18,750
1
20/60
6,250
...........................................................
........................
........................
........................
29,850
tkelley on DSK3SPTVN1PROD with NOTICES
Total ...........................................
Dated: January 6, 2012.
Kimberly Lane,
Reports Clearance Officer, Centers for Disease
Control and Prevention.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[FR Doc. 2012–474 Filed 1–11–12; 8:45 am]
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meetings
BILLING CODE 4163–18–P
National Institutes of Health
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
VerDate Mar<15>2010
16:26 Jan 11, 2012
Jkt 226001
PO 00000
Frm 00027
Fmt 4703
Sfmt 4703
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
E:\FR\FM\12JAN1.SGM
12JAN1
1940
Federal Register / Vol. 77, No. 8 / Thursday, January 12, 2012 / Notices
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; Strategies for the protection
of Pregnant Women and Infants Against
Infectious Diseases (R01)
Date: February 2–3, 2012.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Crowne Plaza Washington DC–
Silver Spring, Silver Spring, MD 20910.
Contact Person: B. Duane Price, Ph.D.,
Scientific Review Officer, Scientific Review
Program, DHHS/NIH/NIAID/DEA, Room
3139, 6700B Rockledge Drive, MSC 7616,
Bethesda, MD 20892, (301) 451–2592,
pricebd@niaid.nih.gov.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; NIAID Investigator Initiated
Program Project Applications (P01).
Date: February 3, 2012.
Time: 1 p.m. to 4 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6700B
Rockledge Drive, Bethesda, MD 20817
(Telephone Conference Call)
Contact Person: Raymond Richard Schleef,
Ph.D., Scientific Review Officer, Scientific
Review Program, Division of Extramural
Activities, National Institutes of Health/
NIAID, 6700B Rockledge Drive, MSC 7616,
Bethesda, MD 20892–7616, (301) 451–3679,
schleefrr@niaid.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Center for
Complementary and Alternative Medicine
Special Emphasis Panel; Clinical Studies of
CAM Therapies.
Date: January 30, 2012.
Time: 1:30 p.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
Boulevard, Bethesda, MD 20892 (Telephone
Conference Call).
Contact Person: Hungyi Shau, Ph.D.,
Scientific Review Officer, National Center for
Complementary and Alternative Medicine,
National Institutes of Health, 6707
Democracy Boulevard, Suite 401, Bethesda,
MD 20892, (301) 402–1030,
Hungyi.Shau@nih.gov.
Name of Committee: National Center for
Complementary and Alternative Medicine
Special Emphasis Panel.
Date: February 24, 2012.
Time: 7 a.m. to 7 p.m.
Agenda: To review and evaluate grant
applications.
Place: Bethesda Marriott Suites, 6711
Democracy Boulevard, Bethesda, MD 20817.
Contact Person: Peter Kozel, Ph.D.,
Scientific Review Officer, NCCAM, 6707
Democracy Boulevard, Suite 401, Bethesda,
MD 20892–5475, (301) 496–8004,
kozelp@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program No. 93.213, Research and Training
in Complementary and Alternative Medicine,
National Institutes of Health, HHS)
Dated: January 5, 2012.
Jennifer S. Spaeth,
Director, Office of Federal Advisory
Committee Policy.
Dated: January 5, 2012.
Jennifer S. Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 2012–460 Filed 1–11–12; 8:45 am]
[FR Doc. 2012–459 Filed 1–11–12; 8:45 am]
BILLING CODE 4140–01–P
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institutes of Health
National Library of Medicine; Notice of
Meetings
tkelley on DSK3SPTVN1PROD with NOTICES
National Center for Complementary
and Alternative Medicine; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
VerDate Mar<15>2010
16:26 Jan 11, 2012
Jkt 226001
Pursuant to section 10(a) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App), notice is
hereby given of a meeting of the Board
of Scientific Counselors, Lister Hill
Center for Biomedical Communications.
The meeting will be open to the
public as indicated below, with
attendance limited to space available.
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
PO 00000
Frm 00028
Fmt 4703
Sfmt 4703
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
The meeting will be closed to the
public as indicated below in accordance
with the provisions set forth in section
552b(c)(6), Title 5 U.S.C., as amended
for review, discussion, and evaluation of
individual intramural programs and
projects conducted by the National
Library of Medicine, including
consideration of personnel
qualifications and performance, and the
competence of individual investigators,
the disclosure of which would
constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Board of Scientific
Counselors, Lister Hill Center for Biomedical
Communications.
Date: April 5–6, 2012.
Open: April 5, 2012, 9 a.m. to 11:30 a.m.
Agenda: Review of research and
development programs and preparation of
reports of the Lister Hill Center for
Biomedical Communications.
Place: National Library of Medicine,
Building 38, 2nd Floor, Board Room, 8600
Rockville Pike, Bethesda, MD 20892.
Closed: April 5, 2012, 11:30 p.m. to 4:30
p.m.
Agenda: To review and evaluate personal
qualifications and performance, and
competence of individual investigators.
Place: National Library of Medicine,
Building 38, 2nd Floor, Board Room, 8600
Rockville Pike, Bethesda, MD 20892.
Closed: April 6, 2012, 8:30 a.m. to 10 a.m.
Agenda: Review of research and
development programs and preparation of
reports of the Lister Hill Center for
Biomedical Communications.
Place: National Library of Medicine,
Building 38, 2nd Floor, Board Room, 8600
Rockville Pike, Bethesda, MD 20892.
Contact Person: Karen Steely, Program
Assistant, Lister Hill Center for Biomedical
Communications, National Library of
Medicine, Building 38A, Room 7S709,
Bethesda, MD 20892, (301) 435–3137.
ksteely@mail.nih.gov.
Open: April 6, 2012, 10 a.m. to 11:30 a.m.
Agenda: Review of research and
development programs and preparation of
reports of the Lister Hill Center for
Biomedical Communications.
Place: National Library of Medicine,
Building 38, 2nd Floor, Board Room, 8600
Rockville Pike, Bethesda, MD 20892.
Contact Person: Karen Steely, Program
Assistant, Lister Hill Center for Biomedical
Communications, National Library of
Medicine, Building 38A, Room 7S709,
Bethesda, MD 20892, (301) 435–3137,
ksteely@mail.nih.gov.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
In the interest of security, NIH has
instituted stringent procedures for entrance
E:\FR\FM\12JAN1.SGM
12JAN1
]]>Agencies
[Federal Register Volume 77, Number 8 (Thursday, January 12, 2012)]
[Notices]
[Pages 1939-1940]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-459]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and Infectious Diseases; Notice of
Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of the following
meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material,
[[Page 1940]]
and personal information concerning individuals associated with the
grant applications, the disclosure of which would constitute a clearly
unwarranted invasion of personal privacy.
Name of Committee: National Institute of Allergy and Infectious
Diseases Special Emphasis Panel; Strategies for the protection of
Pregnant Women and Infants Against Infectious Diseases (R01)
Date: February 2-3, 2012.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant applications.
Place: Crowne Plaza Washington DC-Silver Spring, Silver Spring,
MD 20910.
Contact Person: B. Duane Price, Ph.D., Scientific Review
Officer, Scientific Review Program, DHHS/NIH/NIAID/DEA, Room 3139,
6700B Rockledge Drive, MSC 7616, Bethesda, MD 20892, (301) 451-2592,
pricebd@niaid.nih.gov.
Name of Committee: National Institute of Allergy and Infectious
Diseases Special Emphasis Panel; NIAID Investigator Initiated
Program Project Applications (P01).
Date: February 3, 2012.
Time: 1 p.m. to 4 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 6700B Rockledge Drive,
Bethesda, MD 20817 (Telephone Conference Call)
Contact Person: Raymond Richard Schleef, Ph.D., Scientific
Review Officer, Scientific Review Program, Division of Extramural
Activities, National Institutes of Health/NIAID, 6700B Rockledge
Drive, MSC 7616, Bethesda, MD 20892-7616, (301) 451-3679,
schleefrr@niaid.nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos. 93.855,
Allergy, Immunology, and Transplantation Research; 93.856,
Microbiology and Infectious Diseases Research, National Institutes
of Health, HHS)
Dated: January 5, 2012.
Jennifer S. Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 2012-459 Filed 1-11-12; 8:45 am]
BILLING CODE 4140-01-P
